Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Autolus Therapeutics plc AUTL

Healthcare Biotechnology
Autolus Therapeutics plc is a United Kingdom-based clinical-stage biopharmaceutical company developing programmed T cell therapies for the treatment of cancer and autoimmune diseases. It is focused on chimeric antigen receptor (CAR)-T cell therapy. Using a suite of proprietary and modular T cell programming technologies, it is engineering targeted, controlled and highly active T cell therapy... see more

Recent & Breaking News (NDAQ:AUTL)

Autolus Therapeutics Presents Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2023

GlobeNewswire December 9, 2023

Autolus Therapeutics Submits Biologics License Application to U.S. Food and Drug Administration for obecabtagene autoleucel (obe-cel) for Patients with Relapsed/refractory (r/r) Adult B-Cell Acute Lymphoblastic Leukemia (ALL)

GlobeNewswire November 27, 2023

Autolus Therapeutics to Host Analyst / Investor event at the American Society of Hematology (ASH) Annual Meeting 2023

GlobeNewswire November 15, 2023

Autolus Therapeutics announces participation in upcoming conferences

GlobeNewswire November 6, 2023

Autolus Therapeutics to Present Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2023 in Two Oral Presentations and Two Poster Presentations

GlobeNewswire November 2, 2023

Autolus Therapeutics Reports Third Quarter 2023 Financial Results and Business Updates

GlobeNewswire November 2, 2023

Autolus Therapeutics to host virtual event to discuss the company's obe-cel program in systemic lupus erythematosus

GlobeNewswire October 17, 2023

Correction - Autolus Therapeutics to report third quarter 2023 financial results and host conference call on November 2, 2023

GlobeNewswire October 11, 2023

Autolus Therapeutics to report third quarter 2023 financial results and host conference call on November 2, 2023

GlobeNewswire October 11, 2023

Autolus Therapeutics announces data from AUTO1/22 trial in pediatric Acute Lymphoblastic Leukemia published in the journal Blood

GlobeNewswire September 5, 2023

Autolus Therapeutics Reports Second Quarter 2023 Financial Results and Operational Progress

GlobeNewswire August 3, 2023

Autolus Therapeutics announces appointment of Robert F. Dolski as Chief Financial Officer

GlobeNewswire July 19, 2023

Autolus Therapeutics to report second quarter 2023 financial results and host conference call on August 3, 2023

GlobeNewswire July 18, 2023

Autolus Therapeutics announces a publication in Nature Medicine on obe-cel in Pediatric Acute Lymphoblastic Leukemia

GlobeNewswire July 6, 2023

Autolus Therapeutics announces publication in Cancer Immunology Research

GlobeNewswire June 27, 2023

Autolus Therapeutics strengthens its Board with the appointment of Dr. Robert Iannone as a Non-Executive Director

GlobeNewswire June 20, 2023

Autolus Therapeutics Presents Positive Results from AUTO4 in Relapsed/Refractory TRBC1-Positive Peripheral T-Cell Lymphoma

GlobeNewswire June 16, 2023

Autolus to hold Annual General Meeting (AGM) of Shareholders on Friday, June 30, 2023

GlobeNewswire June 6, 2023

Autolus Therapeutics Presents Positive Results from Pivotal Phase 2 FELIX study in adult r/r B-ALL at ASCO

GlobeNewswire June 2, 2023

Autolus Therapeutics to hold Analyst call to highlight data at ASCO from the Pivotal Phase 2 FELIX study of obe-cel data in adult r/r B-ALL

GlobeNewswire May 22, 2023